Skip to main content
Category

Research

Dr. Reuben
ResearchStories

Clinician Spotlight: Dr. Alexandre Reuben

*April 2024* This month, we are honored to feature Dr Alexandre Reuben, PhD, assistant professor in the Department of Thoracic/Head & Neck Medical Oncology at MD Anderson Cancer Center. Dr. Reuben's research aims to understand how to boost the body's T-cell response against lung cancer, uncovering resistance mechanisms within the…
lung cancer voices
ResearchTreatments

All About Oligoradiation and CURB

*March 2024* In this podcast, Dr. Paul Wheatley-Price sits down with Dr. Amir Safavi, final-year Radiation Oncology Resident at the University of Toronto, and Dr. Jillian Tsai, Staff Radiation Oncologist at Princess Margaret Cancer Centre. They preface the chat with radiation 101, describe what "oligo-" means in the context of…
Targeted Oncology
ResearchTreatments

Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions

*March 2024* The phase 3 MARIPOSA trial (NCT04487080) evaluating a regimen of amivantamab-vmjw (Rybrevant) and lazertinib vs standard-of-care osimertinib (Tagrisso) for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. The combination demonstrated a longer progression-free survival (PFS) and duration…
Oncotarget
ResearchTreatments

From osimertinib to preemptive combinations

*March 2024* Note to reader: Although Tagrisso is the preferred first-line treatment, some patients who took a 1st or 2nd generation drug as first-line (Tarceva, Afatinab) and then Tagrisso as second-line experienced a much longer PFS (progression-free survival) than those who started with Tagrisso. ABSTRACT Here, I suggest that while…
JTO Clinical and Research Reports
ResearchTreatments

Characteristics of Long-Term Survivors with EGFR Mutant Metastatic NSCLC

*March 2024* Abstract Introduction Characteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. Methods Clinical characteristics and outcomes were abstracted from the electronic…
FundingResearchTreatments

Research Update: Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer

*March 2024* Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive cancer growth. Many patients living with EGFR-positive lung cancer benefit from targeted therapies called tyrosine kinase inhibitors (TKIs). TKIs, such as osimertinib, can help…